Charles River Laboratories International (CRL) Non-Current Deferred Tax Liability (2010 - 2025)

Charles River Laboratories International's Non-Current Deferred Tax Liability history runs 14 years deep, the most recent figure standing at $305.9 million for Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability fell 20.02% year-over-year to $305.9 million; the TTM figure through Dec 2025 stood at $305.9 million (down 20.02% YoY), while the FY2025 annual figure was $305.9 million, down 20.02% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2025 stood at $305.9 million, up from $123.0 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $433.1 million in Q4 2022, with the low at $107.3 million in Q1 2025.
• The 5-year median for Non-Current Deferred Tax Liability is $207.2 million (2021), against an average of $219.8 million.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability slumped 55.82% in 2023, then jumped 99.88% in 2024.
• Charles River Laboratories International's Non-Current Deferred Tax Liability stood at $239.7 million in 2021, then jumped by 80.65% to $433.1 million in 2022, then plunged by 55.82% to $191.3 million in 2023, then surged by 99.88% to $382.5 million in 2024, then retreated by 20.02% to $305.9 million in 2025.
• Business Quant data shows CRL's Non-Current Deferred Tax Liability at $305.9 million in Q4 2025, $123.0 million in Q3 2025, and $109.3 million in Q2 2025.